Pharma

Methadone at home? Emerging tech provides new tool in the fight against opioid addiction

Sonara Health’s inexpensive, specially engineered label and web app allow for at-home, digitally supervised dosing of high-cost or high-risks drugs.

By Alexandra Pecci • Sept. 15, 2022

Feds could soon bring COVID-style fight to superbug threat

COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.

By Karissa Waddick • Sept. 13, 2022

Medication affordability’s impact on adherence and outcomes

Improved patient affordability is an important lever that can increase adherence, which in turn can improve health outcomes.

Sept. 12, 2022

Drug recalls are ticking upwards — here’s how to avoid costly pitfalls

Supply chain challenges, labor shortages and increased FDA inspections are boosting recall risks — but careful planning can keep companies in the clear.

By Kelly Bilodeau • Sept. 8, 2022

Pharma’s renewed sickle cell investment lifts a once-shirked disease

Pfizer's $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.

By Kelly Bilodeau • Sept. 1, 2022

Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes

The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.

By Karissa Waddick • Aug. 31, 2022

Parexel joins pharmacy giants in quest to boost community health clinical trials

The Community Alliance Network is the latest industry initiative looking to the pharmacy counter to help improve trial recruitment diversity.

By Taren Grom and Karissa Waddick • Aug. 30, 2022

Hurdles remain in biosims market — but Alvotech is undeterred

The biosimilar developer is advancing a pipeline with high growth potential, including a copycat of Humira.

By Kelly Bilodeau • Aug. 29, 2022

The ‘long COVID’ nightmare: Data-driven alliance offers understanding of the lasting viral impact

A collaboration between Stanford University researchers and Komodo Health aims to advance knowledge of lingering COVID symptoms, health disparities and intervention strategies.

By Michael Gibney • Aug. 29, 2022

Why high-quality medical translations can help save lives

Crystal clear communication is becoming more important for businesses working in our increasingly connected world.

Aug. 29, 2022

With market success at stake, can tech help solve the diversity problem in clinical trials?

Diversity in clinical trials isn’t only important for the health of the overall patient population — it can save millions in lost profits.

By Kelly Bilodeau • Aug. 24, 2022

Woman of the Week: Glympse Bio’s Dr. Tram Tran

How the chief medical officer of the emerging diagnostic company is using the patient perspective as a guiding light.

By Taren Grom • Aug. 24, 2022

Moderna, Eli Lilly and Schrödinger seek to boost financial and people strategies with key new hires

How the latest personnel shifts are impacting each company and the industry at large. 

By Karissa Waddick • Aug. 24, 2022

Overcoming mental health’s drug development challenges with AI

PsychoGenics is leveraging AI-driven drug discovery platforms to advance mental health treatments for schizophrenia, bipolar disorder and treatment-resistant depression.

By Kelly Bilodeau • Aug. 23, 2022

First 90 Days: Agios Pharmaceuticals’ Brian Goff

The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.

By Alexandra Pecci • Aug. 22, 2022

Patents, pandemics and pricing: a peek at the top drug from every big pharma

A look at how the biggest pharma companies in the world and their top-selling drugs fared in the first half of the year.

By Michael Gibney • Aug. 22, 2022

3 ways pharma can prep for Biden’s sweeping drug pricing policies

Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.

By Karissa Waddick • Aug. 18, 2022

Woman of the Week: Takeda Oncology’s Teresa Bitetti

Upon joining Takeda Pharmaceuticals as president of the global oncology unit, Teresa Bitetti had two important goals: to transform the business and create greater synergies between commercial and R&D operations.

By Taren Grom • Aug. 17, 2022

The CEO in the ophthalmologist’s coat

In balancing two roles — Lexitas CEO and practicing physician — George Magrath brings a patient-first perspective to developing and advancing eye treatments.

By Alexandra Pecci • Aug. 16, 2022

Right under our noses: Could COVID-19 vaccines be better as nasal spray?

Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.

By Kelly Bilodeau • Aug. 16, 2022

The FDA is mulling an OTC approval for a birth control. Will politics factor in?

Analysts are watching how cultural and political debates around reproductive rights may impact HRA Pharma's OTC birth control application.

By Karissa Waddick • Aug. 15, 2022

Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics

Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.

By Michael Gibney • Aug. 11, 2022

As pharma M&A ramps up, U.S. execs are bullish on more deals

What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

By Michael Gibney • Aug. 11, 2022

4 ways to nail the launch of your cell therapy

A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

By Meagan Parrish • Aug. 10, 2022

How real world evidence is impacting rare disease drug development

ICON’s Will Maier shares how a more patient-focused approach to trials is leading to alternatives for randomization.

By Kim Ribbink • Aug. 9, 2022